CONCANNON BRIAN 4

Accession 0001127602-22-003422

CIK 0000816956other

View on SEC.gov Company Profile

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 5:12 PM ET

Size

40.2 KB

Accession

0001127602-22-003422

Insider Transaction Report

Form 4

Period: 2022-02-02

CONMED CorpCNMD

CONCANNON BRIAN

Director

Transactions

Sale
Common Stock
2022-02-02$135.09/sh−2,027$273,827→ 13,400 total
Sale
Common Stock
2022-02-02$136.96/sh−4,200$575,232→ 9,200 total
Sale
Common Stock
2022-02-02$137.91/sh−200$27,582→ 9,000 total
Exercise/Conversion
Common Stock
2022-02-02$69.03/sh+2,549$175,957→ 11,549 total
Sale
Common Stock
2022-02-02$135.08/sh−2,549$344,319→ 9,000 total
Exercise/Conversion
Common Stock
2022-02-02$79.94/sh+2,165$173,070→ 11,165 total
Sale
Common Stock
2022-02-02$135.08/sh−2,165$292,448→ 9,000 total
Exercise/Conversion
Common Stock
2022-02-02$73.94/sh+1,843$136,271→ 10,843 total
Sale
Common Stock
2022-02-02$135.06/sh−1,843$248,916→ 9,000 total
Exercise/Conversion
Common Stock
2022-02-02$33.43/sh+1,000$33,430→ 10,000 total
Exercise/Conversion
Options To Purchase Common Stock
2022-02-02−1,843→ 0 total
Exercise: $73.94From: 2021-06-01Exp: 2030-06-01→ Common Stock (1,843 underlying)
Exercise/Conversion
Sars (Stock Appreciation Rights)
2022-02-02−1,000→ 0 total
Exercise: $39.64From: 2015-06-01Exp: 2024-09-11→ Common Stock (1,000 underlying)
Tax Payment
Common Stock
2022-02-02$139.03/sh−241$33,506→ 9,759 total
Exercise/Conversion
Common Stock
2022-02-02$39.64/sh+1,000$39,640→ 10,759 total
Tax Payment
Common Stock
2022-02-02$139.03/sh−286$39,763→ 10,473 total
Exercise/Conversion
Common Stock
2022-02-02$55.70/sh+1,000$55,700→ 11,473 total
Tax Payment
Common Stock
2022-02-02$139.03/sh−401$55,751→ 11,072 total
Exercise/Conversion
Options To Purchase Common Stock
2022-02-02−2,549→ 0 total
Exercise: $69.03From: 2019-06-01Exp: 2028-06-01→ Common Stock (2,549 underlying)
Exercise/Conversion
Options To Purchase Common Stock
2022-02-02−2,165→ 0 total
Exercise: $79.94From: 2020-06-01Exp: 2029-06-03→ Common Stock (2,165 underlying)
Exercise/Conversion
Sars (Stock Appreciation Rights)
2022-02-02−1,000→ 0 total
Exercise: $33.43From: 2014-06-01Exp: 2023-07-26→ Common Stock (1,000 underlying)
Exercise/Conversion
Sars (Stock Appreciation Rights)
2022-02-02−1,000→ 0 total
Exercise: $55.70From: 2016-06-01Exp: 2025-06-01→ Common Stock (1,000 underlying)

Footnotes (10)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.83. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
[F10]The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting upon completion of the term of service.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.29 to $137.06. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.88 to $137.94. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.82. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.84. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
[F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.12. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
[F7]The incentive stock options ("ISOs") were granted under the Company's 2016 Amended and Restated Non-Employee Director Equity Compensation Plan and generally vest 100% after a one year period.
[F8]The stock options were granted under the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan and generally vest 100% after a one year period.
[F9]The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 100% after a one year period.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

CONMED Corp

CIK 0000816956

→

Entity typeother

Related Parties

filerCIK 0001261784

Filing Metadata

Form type: 4
Filed: Feb 3, 7:00 PM ET
Accepted: Feb 4, 5:12 PM ET
Size: 40.2 KB

View on SEC.gov